In 2009, an editorial by Putman focused on the dramatic increase in the use of proton pump inhibitors (PPIs) in infants [1]. Considering the increasing evidence that PPIs offer little benefit for most of the symptoms for which they are prescribed, Putman strongly highlighted the need for a serious effort to curtail their empiric use. The editorial was linked to a study by Orenstein et al, which...

Proton pump inhibitors (PPIs) increase osteoporotic fracture risk presumably via hypochlorhydria and consequent reduced fractional calcium absorption (FCA). Existing studies provide conflicting information regarding the direct effects of PPIs on FCA. We evaluated the effect of PPI therapy on FCA. We recruited women at least 5 years past menopause who were not taking acid suppressants. Participa...

5 roton pump inhibitors (PPIs) suppress gastric acid secretion by selectively inhibiting the enzyme P hydrogenepotassium adenosine triphosphatase, located in gastric parietal cells. These drugs superseded H2-receptor antagonists as first-line acid suppressants in the 1980s, and their potent effect has revolutionised the management of common upper gastrointestinal (GI) disorders, including gastr...

Coronary Artery Disease (CAD) patients to decrease the incidence of cardiovascular events.1 Above all, mucosal injuries associated with inhibition of prostaglandin synthesis, resulting in GI ulceration and bleeding, is a major side effect of the drug.1 Therefore, a concomitant use of Aspirin and Proton Pump Inhibitors (PPIs) has been approved for CAD patients to prevent mucosa associated disord...

OBJECTIVES To investigate the cost effectiveness of cyclo-oxygenase-2 (COX 2) selective inhibitors and traditional non-steroidal anti-inflammatory drugs (NSAIDs), and the addition of proton pump inhibitors to these treatments, for people with osteoarthritis. DESIGN An economic evaluation using a Markov model and data from a systematic review was conducted. Estimates of cardiovascular and gast...

M any findings support a possible association between gastroesophageal reflux disease (GERD) and asthma in children, but there is not enough evidence to support the causality of this association. Longitudinal studies with long-term follow-up are urgently required to cover the many gaps that persist in this area. Treatment of GERD with proton pump inhibitors (PPIs) in children with uncontrolled ...

Objective: To discuss the role of a proton pump inhibitor (pantoprazole) as a cause of night sweats in an older person. Methods: Our case involves a 73 year-old man who experienced night sweats while taking pantoprazole to treat gastroesophageal reflux disease. Results: Night sweats disappeared ten days after ceasing pantoprazole. They recurred two months later, one week after recommencing pant...

Gastroesophageal reflux induced cough is a common cause of chronic cough, and proton pump inhibitors are a standard therapy. However, the patients unresponsive to the standard therapy are difficult to treat and remain a challenge to doctors. Here, we summarized the experience of successful resolution of refractory chronic cough due to gastroesophageal reflux with baclofen in three patients. It ...

M etformin and proton pump in-hibitors have been implicated in decreasing levels of vitamin B 12 independently. The purpose of this study was to evaluate the effect of concomitant use of metformin and proton pump inhibitors on the incidence of vitamin B 12 deficiency. A retrospective chart review was done using the computerized patient record system at the Memphis VA Medical Center for 614 pati...